Draegerwerk AG & Co. KGaA · XETR:DRW8
Draegerwerk AG & Co. KGaA — Drägerwerk AG & Co. KGaA — Investor Presentation (November 2003)
74 slides from Draegerwerk AG & Co. KGaA's investor presentation, November 2003
Slide 1: Dräger Group
Dräger Group November 2003 1 November, 03
Slide 2: Contents
Contents 1. Dräger Group 2. Dräger Medical 3. Dräger Safety 4. Dräger Aerospace 5. Financials of the Dräger Group 6. Appendix 2 November, 03
Slide 3: Dräger Group
Dräger Group »Technology for Life« 3 November, 03
Slide 4: Dräger – Technology for Life
Dräger – Technology for Life Dräger is a worldwide leading company that develops and provides technology and services to protect and maintain human life. Our innovative products monitor, support and protect the vital functions in human beings. They create better and safer conditions for both our hea
Slide 5: Legal Structure 2002
Legal Structure 2002 Drägerwerk AG Holding 100 % 100 % 100 % Dräger Medical Dräger Safety Dräger Aerospace Verwaltungs AG Verwaltungs AG GmbH (sold 2003) 65 % 100 % Dräger Medical Dräger Safety Service companies • Dräger Synematic GmbH AG & Co KGaA AG & Co KGaA • Nordac GmbH • Dräger Interservices G
Slide 6: Business Sectors
Business Sectors Dräger Medical Dräger Safety Dräger Aerospace (sold in 2003) Worldwide No. 1 or 2 in World market leader for heavy anesthesia, ventilation respiratory protection equipment and neonatal care (compressed-air breathing apparatus and long-term ventilation) and electronic sensors Europea
Slide 7: Global Presence
Global Presence Sales and service network: Sales volume per region in 2002 Subsidiaries in 40 countries Represented in another 150 countries Asia/Australia 13,0% The Americas 18,1% Long-term customer relationships Africa 2,0% 40% of our workforce employed Rest of Europe 9,7% outside Germany Germany
Slide 8: Global Presence (production locations)
Globale Presence (production locations) Lübeck Hagen Danvers Telford Safety Medical Medical Svenljunga Blyth Beijing Safety Safety Safety Plymouth Safety Shanghai Medical Best Medical Pittsburgh Safety Notting Hill Safety Most important production locations 8 November, 03
Slide 9: Goals 2006
Goals 2006 Securing and further extension of the worldwide leading market position Customer-oriented innovative products and services Stronger penetration of growth markets Asia/USA Turnover growth: 6% p. a. Optimization of the business processes EBIT margin > 10.0% ROCE > 20.0% Securing of independ
Slide 10: Dräger Medical
Dräger Medical »Because you care« 10 November, 03
Slide 11: Core Business: Solutions for the Acute Point of Care and Home Care
Core Business: Solutions for the Acute Point of Care (APOC) and Home Care Pre-Hospital Hospital Post Hospital Emergency Care OR / Anesthesia CriticalCare HomeCare • Ventilation • Anesthesia • Ventilation • Oxygen therapy • Monitoring • Monitoring • Incubators • Sleep therapy • Neonatal Transport • I
Slide 12: The situation in summer 2000
The situation in summer 2000 Sales 900 800 732 Symptoms 700 660 591 600 509 547 Mio Euro 500 – CAGR of 10%, but mainly 400 outside the core business 300 200 – Progressively rising capital 100 employed and decreasing 0 96 97 98 99 00 EBIT resulted in a growing negative Cash Flow EBIT 60 – Long develo
Slide 13: Goals of the restructuring program
Goals of the restructuring program Focus: – Definition of ›Acute-Point-of-Care‹ and ›Home Respiratory Support‹ as core business, goal: to be a leading player in all business segments Market/customers: – Intensify customer relationships and utilize chances in USA and Asia – Transformation from a manu
Slide 14: Three Phases of Restructuring
Three Phases of Restructuring – Phase 1: Deep cuts and focus (9/2000 to 6/2001) – Phase 2: On the way to Business Excellence (7/2001 to 2006) - Introduction of global business processes - Innovation initiative - Extension of the worldwide sales and service organization – Phase 3: Active participatio
Slide 15: Phase 1: September 2000 to June 2001
Phase 1: September 2000 to June 2001 • New management, especially in Germany • Focus on the core business APOC • 13% downsizing of workforce in Germany, 420 employees worldwide • Sale and closing down of companies • Restructuring of business fields “IT” and “Managed Hospital Services” • Organization
Slide 16: Three Phases of Restructuring
Three Phases of Restructuring – Phase 1: Deep cuts and focus (9/2000 to 6/2001) – Phase 2: On the way to Business Excellence (7/2001 to 2006) - Introduction of global business processes - Innovation initiative - Extension of the worldwide sales and service organization – Phase 3: Active participatio
Slide 17: Phase 2: The process house - global business processes
Phase 2: The process house - 5 global business processes Strategy Innovation Lifecycle Mgmt. Installed Order Order Mgmt. Base Generation Fulfillment Incl. servicing, From the creation From the idea From stable From customer maintenance, of a demand to to stable installed base order to receipt of rep
Slide 18: Phase 2: Introduction of global processes
Phase 2: Introduction of global processes Examples: Innovation process: Spare parts logistics within the process “Mgmt. Installed Base”: • reduce the development time by 50% • modular product design • supply 95% of the orders directly to the technician within 24 hours • reduction of the number of su
Slide 19: Phase 2: Innovation Initiative
Phase 2: Innovation Initiative Approximately 50% of the main products are younger than 3 years 19 November, 03
Slide 20: Phase 2: Extension of the worldwide sales and service network
Phase 2: Extension of the worldwide sales and service network • Establishment of 6 subsidiaries: - Asia: China Trading Company, Thailand, Hong Kong, Taiwan - Europe: Sweden, Ireland • 300 people employed in sales and service organization abroad • Establishment of an Intranet to provide latest produc
Slide 21: Highlights 2002: First effects of Phase 2
Highlights 2002: First effects of Phase 2 • Definition of global business processes and first implementation measures (order fulfillment, spare parts, innovation process, order generation) • Innovation initiative rejuvenates product portfolio. Already about half of the products are younger than thre
Slide 22: Key Figures
Key Figures in million € 2000 2001 2002 CAGR Net sales 732 805 848 7,6 % R&D expenditure 50 48 52 2,1 % EBITDA 29* 59 91 77 % EBIT 9* 39 75 > 100 % EBIT margin 1,2* % 4,8 % 8,9 % Capital Employed*** 350 316 301 ROCE 2,6* % 12,3 % 25,0 % Employees (average) 4.868 4.837 4.934** * Without restructuring
Slide 23: Market Trends
Market Trends • Increasing worldwide consolidation of the suppliers in the market segment Acute-Point-of-Care (APOC) and Home Respiratory Care • Hospitals shape the market through - increasing purchasing power through consolidation activities - demand for process-supporting solutions - increasing sp
Slide 24: Market Volume
Market Volume World medical device market €250 billion The world APOC and Home Respiratory Care CAGR: 2% by 2004e market €17 billion CAGR: 2-4% by 2004e 3% 8% 3% 2% 8% 6% 20% 5% 7% 30 % 7% 9% 12% 2% 27% 13% 7% 4% 2% 25 % Acute Point of Care and HC-Ventilation Disposables/Reusables Anesthesia Systems
Slide 25: Three Phases of Restructuring
Three Phases of Restructuring – Phase 1: Deep cuts and focus (9/2000 until 6/2001) – Phase 2: On the way to Business Excellence (7/2001 until 2006) - Introduction of global business processes - Innovation initiative - Extension of the worldwide sales and service organization – Phase 3: Active partic
Slide 26: Phase 3: Active participation in the consolidation process
Phase 3: Active participation in the consolidation process Siemens AG Drägerwerk AG Siemens Medical Solutions ... Joint Venture ... EM MR CT US HS ... 26 November, 03
Slide 27: Phase 3: The Joint Venture with Siemens-EM
Phase 3: The Joint Venture with Siemens-EM Drägerwerk AG Siemens AG 65% 35% Dräger Medical AG & Co. KGaA Dräger Med Dräger Med Dräger Med Dräger Med ... Inc. S.A. Ltd. N.V. Consolidation at Drägerwerk AG 27 November, 03
Slide 28: Competitors (by sales volume)
Competitors (by sales volume) le t&Tab ble igh Ca re eusa g ORL a i y apy R rin ion s + es n c her p & onito ntilat fusion chSy sth erge ing T Dis M Ve In Ar Ane Em rm OCI T W a AP Tyco ? (?) ? (?) ? GE Medical (incl. Instrumentarium, Spacelabs, Soxyl) (?) ? (?) ? (?) ? ? Dräger Medical (?) ? ? (?)
Slide 29: The worldwide sales and service network of the JV
The worldwide sales and service network of the JV Lübeck Best Danvers Shanghai Telford • 5,700 employees • represented in more than 190 countries worldwide • 2,800 in sales and service • R&D and production locations ( ) • sales and service subsidiaries ( ) 29 November, 03
Slide 30: Advantages of the Joint Venture from the customer's point of view
Advantages of the Joint Venture from the customer‘s point of view • A complete product portfolio at the Acute Point of Care: Stand-alone devices, process-supporting solutions and services for emergency care, the operating room, intensive care, neonatal care and HomeCare • Optimization of the clinica
Slide 31: Advantages of the Joint Venture, strategic perspectives
Advantages of the Joint Venture, strategic perspectives • Expand the technology portfolio by integrating the Siemens expertise in patient monitoring • Develop process-supporting solutions at the Point-of-Care that help to reduce the clinical process cost while at the same time increasing the quality
Slide 32: Key Figures 2003e / 2004e
Key Figures 2003e / 2004e in million € Q3 2002 Q3 2003 2003e 2003e 2004e w/o JV with JV Order intake 617,2 654,8 - - - Net sales 552,5 597,7 876 940 1.200 EBITDA 44,0 43,1 1) 102 112 2) 162 2) EBIT * 32,3 42,4 2) 85 95 2) 145 2) EBIT margin 5,8% 7,1% 9,7% 10,1% 12,1% 3) 3) Net profit 16,3 16,7 46 36
Slide 33: Competitive Advantages
Competitive Advantages brand name Dräger Medical: worldwide known for quality and innovation global sales and service network, long-term customer relationships large installed base global orientation of business processes extensive product portfolio allows process-optimizing solutions 33 November, 0
Slide 34: Dräger Safety
Dräger Safety »Pioneering Solutions« 34 November, 03
Slide 35: Products and Services
Products and Services 35 November, 03
Slide 36: Business Model
Business Model Fire Brigades Mining, Public Government Industry Rescue Services Utility Companies Institutions Customers Demand/ Products, systems, worldwide efficient direct service/sales, training Offer Suppliers of System Solutions (Pioneering Solutions) Gas Detection Technology Dräger Safety + P
Slide 37: Highlights 2002
Highlights 2002 – Again clear increase of net sales and profit – Worldwide standardization/optimization of the business processes – Expanding of market position and innovative power through e.g. • Intensive expansion of the worldwide sales and service network (+ 200 employees worldwide) • Acquisitio
Slide 38: Key Figures
Key Figures in million € 2000 2001 2002 CAGR Net Sales 382 425 471 11,0 % R&D expenditures 19 20 21 5,2 % EBITDA 39 42 53 16,6% EBIT 27 30 40 21,7 % EBIT margin 7,2 %. 7,1 % 8,7 % - Capital Employed* 146 156 150 ROCE 18,7 % 19,2 % 24,8 % Employees (average) 2.816 3.030 3.289 * Capital Employed w/o l
Slide 39: Market Volume (own estimate)
Market Volume (own estimate) NAFTA NAFTA 641 Mio € 654 Mio € Asia Pacific Asia/Pacific 635 Mio € 680 Mio € EU 1 EU 2 EU 1 EU 2 339 Mio € 626 Mio € 311 Mio € 672 Mio € 2001 2004e Total: €2.21 billion Total: €2.34 billion Dräger Safety market share: 19.2% Dräger Safety market share: approx. 21.6% Euro
Slide 40: Competitors (relevant sales volume)
Competitors (relevant sales volume) Gas Detection Technology Personal Protection Services Tyco ˜ ˜ MSA/Auer ˜ ˜ (˜) 3M ˜ Dräger Safety ˜ ˜ ˜ Bacou/Dalloz ˜ Zellweger/Analystics ˜ (˜) BW ˜ Lions ˜ Crowcon ˜ ˜ Complete portfolio ( ) Partial presence 40 November, 03
Slide 41: Market Trends
Market Trends – Increasing environmental consciousness – Increasing safety consciousness – Focus on a few suppliers due to worldwide consolidation – Increasing demand for complex services in contrast to just products – Increasing importance of facility protection – Total Care/one-stop-shopping: over
Slide 42: Strategy
Strategy – Establish Dräger Safety as a supplier of system solutions – Expansion of the technological leadership by a higher degree of innovation – Growth in sales > market growth through predatory competition (innovation leader, cost leadership, complete service portfolio) – Optimization of the sal
Slide 43: Strategy Implementation
Strategy Implementation Higher innovation rate Time-to-market 2000: 2% of products not older than 12 months 2000: 34 months 2002: 5% of products not older than 12 months 2002: 29 months 2004e: 10% of products not older than 12 months 2004e: < 24 months Sales growth vs. market growth 2000 ð 2002 ð 20
Slide 44: Strategy Implementation – Optimization of the sales strategy
Strategy Implementation – Optimization of the sales strategy • Worldwide network for direct sales / services • Expansion of the distributor network (depending on the region) • More intense utilization of the Internet (B2B / market places) • Service organization as promoter • New partnerships / strat
Slide 45: Strategy Implementation – Portfolio of comprehensive system solutions
Strategy Implementation – Portfolio of comprehensive system solutions • From maintenance up to operator models Advanced training Modular Products Service Financing Individual Solutions Efficiency e.g. Safety Service Center, Port of Rotterdam, i.e. maintenance, exchange, completion of safety-relevant
Slide 46: Key Figures 2003e / 2004e
Key Figures 2003e / 2004e in Mio € Q3 2002 Q3 2003 2003e 2004e Order Intake 352,0 361,3 - - Net sales 343,6 339,5 460 505 EBITDA 40,4 35,2 56 64 EBIT 31,1 24,9 39 47 EBIT margin 9,1% 7,3% 8,5% 9,3% Net income 20,0 15,5 24 29 Capital Employed 164,8 176,5 171 181 ROCE 18,9% 14,1% 22,8% 26,0% Employees
Slide 47: Competitive Advantages
Competitive Advantages global/direct sales and service network Performance technology and cost leadership Market worldwide adaptation of equipment to regional/national standards supplier of system solutions customer defines the services offered 47 November, 03
Slide 48: Dräger Aerospace
Dräger Aerospace 48 November, 03
Slide 49: Dräger Aerospace at a glance
Dräger Aerospace at a glance in million € 2000 2001 2002 Net sales 25,2 28,2 24,5 EBIT 1,0 0,4 - 2,9 EBIT margin 4,0 % 1,4 % - 11,8 % Capital Employed 9,3 7,2 6,8 ROCE 10,6 % 5,6 % - 42,6 % Employees (average) 187 201 198 – 2003 sold to cooperation partner Cobham plc – Purchasing price: 28,4 million
Slide 50: Financials of Drägerwerk AG
Financials of Drägerwerk AG 50 November, 03
Slide 51: Group at a glance
Group at a glance in million € 2000 2001 2002 2002* CAGR* Net sales 1.137 1.257 1.333 1.333 8,3 % R&D expenditure 72 73 78 78 4,1 % EBITDA 77 96 111 112 20,6 % EBIT 30 49 65 66 48,3 % EBIT margin 2,6 % 3,9 % 4,8 % 5,0 % Annual net profit - 59 10 20 20 Capital Employed 543 535 489 530 ROCE 5,5 % 9,2
Slide 52: Profit and Loss Account for the Group
Profit and Loss Account for the Group in million € 2000 2001 2002 Net sales 1.137 1.257 1.333 Total operating performance 1.125 1.271 1.340 Cost of materials 387 458 470 in % of the total oper. perform. 34,4 % 36,0 % 35,1 % Personnel expenses 502 504 529 in % of the total oper. perform. 44,6 % 39,7
Slide 53: Cash Flow Group
Cash Flow Group in million € 2000 2001 2002 Annual net profit/loss - 59 10 20 Cash Flow by operating activities 31 77 105 Cash Flow/ share 2,44 EUR 6,06 EUR 8,27 EUR Cash Flow from investing activities - 45 - 48 - 50 Free Cash Flow - 14 28 55 53 November, 03
Slide 54: Group Capital Expenditure
Group Capital Expenditure in million € 2000 2001 2002 Immaterial assets 5 10 8 Tangible assets 43 34 40 Financial assets 6 5 3 Total 54 49 51 54 November, 03
Slide 55: Development of Balance Sheet for the Group
Development of Balance Sheet for the Group in million € in million € Assets 31.12.2001 31.12.2002 Total equity & liabilities 31.12.2001 31.12.2002 Total Equity 172 170 Assets 215 201 Pension accruals 123 129 Other accruals 142 154 Inventories 223 213 Trade receivables 341 343 Financial liabilities 2
Slide 56: Development of Balance Sheet by JV
Development of Balance Sheet by JV BALANCE SHEET 30.09.2003 31.12.2002 01.07.2003 in million € Changes JV Fixed assets 208,0 201,0 4,0 Inventories 268,0 213,0 24,1 Trade receivables 329,7 342,7 27,4 Cash & cash equivalents 71,1 42,4 - All other assets 346,2 46,4 355,6 Total assets 1.223,0 845,5 411,
Slide 57: Prospects for the Group 2003e/2004e
Prospects for the Group 2003e/2004e in million € Q3 2002 Q3 2003 2003e 2003e 2004e with JV Order intake 987,8 1.027,1 - - - Net sales 909,4 949,2 1.383 1.415 1.738 1) EBITDA 74,5 75,6 138 153 209 1) EBIT 42,5 43,0 88 98 154 EBIT margin 4,7% 4,5% 7,8 % 6,9 % 8,9 % 4) 6) Net profit 12,1 34,4 47 37 2)
Slide 58: Appendix
Appendix 58 November, 03
Slide 59: Dräger Service Companies
Dräger Service Companies 59 November, 03
Slide 60: Dräger Service Companies – Internal Outsourcing (1/2)
Dräger Service Companies– Internal Outsourcing (1/2) in million € 2001 2002 Dräger Electronics GmbH Net sales 27,5 23,4 Net sales with third parties 1,8 1,2 EBIT - 4,3 - 2,1 Employees (average) 134 125 Dräger Interservices GmbH Net sales 26,1 32,1 Net sales with third parties 0,3 0,3 EBIT 2,0 2,4 Em
Slide 61: Dräger Service Companies – Internal Outsourcing (2/2)
Dräger Service Companies– Internal Outsourcing (2/2) in million € 2001 2002 Nordac GmbH Net sales 12,9 20,8 Net sales with third parties 4,4 5,0 EBIT 1,2 1,5 Employees (average) 31 50 DrägerForum GmbH Net sales 4,8 4,4 Net sales with third parties 1,2 1,1 EBIT 0,3 0,3 Employees (average) 34 29 Dräge
Slide 62: Historic Milestones (1)
Historic Milestones (1) 1889-1910: The Pioneers n Founded by Heinrich Dräger in 1889 n Early specialization in pressure control, medical and safety technology From 1902 until today: continuous development of worldwide leading technologies n 1902: Development of first anesthesia system n 1904: Develo
Slide 63: Historic Milestones (2)
Historic Milestones (2) n 1951: Development of the first portable incubator n 1955: Development of the first breath alcohol measuring instrument n 1981: Development of the first electronic gas detection system n 1985: Development of the Space Shuttle filter system n 1989: Development of the first an
Slide 64: Historic Milestones (3)
Historic Milestones (3) Since 1991: focus on the reorganization of the Group structure n Foundation of the Holding company n Separation of the two core business sectors and reorganization into independent KGaA companies in order to attract new investors n Spin-off of the internal service activities
Slide 65: Management
Management 65 November, 03
Slide 66: Board of Management Drägerwerk AG Holding (1)
Board of Management of Drägerwerk AG Holding (1) n Theo Dräger (Chairman of the Board of Drägerwerk AG) with the company since 1968 Main responsibilities: Company spokesman Group Strategy, Legal Affairs, Public Relations, M+A n Stefan Dräger (Member of the Board of Drägerwerk AG) with the company si
Slide 67: Board of Management Drägerwerk AG Holding (2)
Board of Management Drägerwerk AG Holding (2) n Prof. Dr. Albert Jugel (President and CEO of Dräger Safety AG & Co. KGaA) with the company since 1999, working in the business since 1978, former employers: Robotron, Technische Universität Dresden, FUBA n Ingo Gensch (Member of the Board of Drägerwerk
Slide 68: Members of the Board of the Sub-Groups
Members of the Board of the Sub-Groups n Roland Jaksch (Chief Finanical Officer of Dräger Medical AG & Co. KGaA) with the company since 2002, working in the business since 1982, former employer: Siemens n Thomas Holzgreve (Chief Financial Officer of Dräger Safety AG & Co. KGaA) with the company sinc
Slide 69: Development of the Company Structure
Development of the Company Structure until 1990 1991-1996 1997-2001 Drägerwerk AG Drägerwerk AG Drägerwerk AG Holding Production MT ST DAe Sales MT ST DAe R&D GmbH GmbH GmbH Administration Service companies Service companies • Synematic GmbH • Synematic GmbH • Nordac GmbH • Nordac GmbH • Interservic
Slide 70: Facts about the shares
Facts about the shares n Stock markets: XETRA, Frankfurt, Stuttgart, Düsseldorf, Munich,Hamburg n Index: TecDAX n ISIN: DE 000 555 0636 n Number of shares: 6.350.000 (preferred stocks) 100 % free float 6.350.000 (common stocks) 100 % Dräger family n High: 48,10 € (31.10.02-31.10.03) n Low: 15,25 € (
Slide 71: Share price: Drägerwerk AG Preferred Stock
Share price: Drägerwerk AG Preferred Stock 71 November, 03
Slide 72: Financial Calendar
Financial Calendar 13.11.2003 - Q3/2003 report - Conference Call 13.05.2004 - Accounts press conference, Lübeck - Analysts' meeting, Frankfurt - Q1/2004 report 11.06.2004 - Annual stockholders´ meeting, Lübeck 12.08.2004 - H1/2004 report - Conference Call 11.11.2004 - Q3/2004 report - Conference Cal
Slide 73: Contact Persons
Contact Persons Hans-Oskar Sulzer Dr. Welf Böttcher Vanina Herbst Chief Financial Officer Head of Corporate Communications Investor Relations Drägerwerk Aktiengesellschaft Drägerwerk Aktiengesellschaft Drägerwerk Aktiengesellschaft Moislinger Allee 53-55 Moislinger Allee 53-55 Moislinger Allee 53-55
Slide 74: Disclaimer
Disclaimer Estimates: This presentation contains a number of forecasts and estimates which are based on present expectations, anticipations and predictions on the part of the Executive Board and the information it currently has. Such estimates should not be construed as a warranty that the future de
Drägerwerk AG & Co. KGaA — Investor Presentation (November 2003) on 6ix